NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning
30 December 2025
1 min read

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning

NEW YORK, December 30, 2025, 05:51 ET — Premarket

  • NIO shares were up about 0.2% at $5.35 in premarket trading.
  • Reports on battery sourcing and new-model momentum kept the China EV maker in focus into year-end.
  • Traders are watching for the next monthly delivery update and signs demand holds up as incentives fade.

NIO’s U.S.-listed shares edged up 0.2% to $5.35 in premarket trading on Tuesday, based on Public.com data. 1

The stock is drawing attention as investors weigh signs that China’s electric-vehicle market may cool after year-end incentives. “Demand for new energy batteries will drop drastically from the end of this year,” Cui Dongshu, secretary general of China’s passenger car association, wrote in a social media post cited by Reuters. 2

Battery terms matter because packs are a major cost in an EV, and supplier concentration can reshape pricing power. For makers selling into a competitive China market, cost control and delivery momentum tend to show up quickly in margins and cash needs.

S&P Global’s AutoTechInsight reported on Monday that NIO has adjusted its battery supply strategy, reversing earlier efforts to reduce dependence on Contemporary Amperex Technology (CATL) and halting a collaboration with BYD’s FinDreams Battery. 3

The Business Times reported NIO will lean more heavily on CATL for packs used across brands, citing industry publication CnEVPost and a local media report. It said the shift includes 85 kilowatt-hour (kWh) batteries — a measure of battery capacity — for the Onvo L60 SUV, along with larger 100 kWh packs for the Nio-branded lineup. 4

Model momentum has also been part of the narrative. CnEVPost reported that NIO said on its social media accounts it delivered the 40,000th third-generation ES8, a flagship sport-utility vehicle, roughly 100 days after deliveries began. 5

NIO ended Monday up 4.71% at $5.34, extending the stock’s third straight daily gain, according to MarketWatch. Trading volume reached 68.3 million shares, above its 50-day average of 48.0 million, while the stock remained about a third below its 52-week high of $8.02. 6

In early trading indications, other U.S.-listed China EV names were softer: Li Auto was down about 1.6% and XPeng was down about 1.4%.

From a chart perspective, NIO has been working inside a 52-week range of roughly $3.02 to $8.02, with the latest regular-session range around $5.08 to $5.38, according to Investing.com data. 7

Investors are now looking for the next monthly delivery report, typically released at the start of each month, for a read on demand heading into 2026. NIO last said it delivered 36,275 vehicles in November, including deliveries from its NIO, ONVO and firefly brands. 8

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open
Previous Story

Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

Tesco gives away free apples for kids in 800 UK stores as New Year health push begins
Next Story

Tesco gives away free apples for kids in 800 UK stores as New Year health push begins

Go toTop